Wilmington Savings Fund Society FSB Acquires New Shares in CRISPR Therapeutics AG (NASDAQ:CRSP)

Wilmington Savings Fund Society FSB bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 850 shares of the company’s stock, valued at approximately $40,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Baker BROS. Advisors LP lifted its stake in CRISPR Therapeutics by 743.1% during the third quarter. Baker BROS. Advisors LP now owns 843,075 shares of the company’s stock worth $39,608,000 after purchasing an additional 743,075 shares in the last quarter. State Street Corp boosted its holdings in CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after acquiring an additional 599,304 shares during the period. Farallon Capital Management LLC acquired a new position in CRISPR Therapeutics in the 2nd quarter valued at about $28,625,000. Marshall Wace LLP purchased a new stake in CRISPR Therapeutics during the second quarter worth about $10,078,000. Finally, Private Advisor Group LLC lifted its position in shares of CRISPR Therapeutics by 472.9% during the second quarter. Private Advisor Group LLC now owns 77,627 shares of the company’s stock worth $4,193,000 after purchasing an additional 64,076 shares in the last quarter. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CRSP. Needham & Company LLC restated a “buy” rating and issued a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Chardan Capital reaffirmed a “buy” rating and set a $94.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. JMP Securities reiterated a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a report on Friday. Barclays cut their price target on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. Finally, StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a research note on Wednesday, December 11th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Hold” and an average target price of $77.93.

Insider Activity at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $198,680.04. Following the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at $10,484,271.20. This trade represents a 1.86 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel James R. Kasinger sold 1,089 shares of the stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $50,398.92. Following the transaction, the general counsel now directly owns 62,597 shares of the company’s stock, valued at $2,896,989.16. This represents a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,382 shares of company stock worth $2,744,179 in the last quarter. Company insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Trading Up 0.8 %

Shares of CRSP opened at $40.72 on Monday. The company’s 50 day simple moving average is $48.45 and its 200-day simple moving average is $50.66. The firm has a market cap of $3.48 billion, a PE ratio of -14.39 and a beta of 1.62. CRISPR Therapeutics AG has a 12-month low of $39.41 and a 12-month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The company had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. During the same period last year, the firm posted ($1.41) EPS. As a group, equities research analysts forecast that CRISPR Therapeutics AG will post -5.13 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.